Jennifer N. Brudno

Oncology · 2016–2018

A researcher in the Science corpus: 5 papers; trusts 12 researchers and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

• Oncology — 115 citations into it; #1,084 of 1,698 by trust here, #729 by citations
• Immunology — 47 citations into it
• Genetics — 39 citations into it; #4,830 of 6,854 by trust here, #2,520 by citations
• Biomedical Engineering — 10 citations into it; #8,094 of 10,734 by trust here, #4,472 by citations
• Hematology — 10 citations into it

Whom Jennifer N. Brudno trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. D. Porter
2. J. Kochenderfer
3. S. Maude
4. R. Brentjens
5. B. Levine
6. R. Morgan
7. I. Rivière
8. C. June
9. M. Dudley
10. Michel Sadelain

Who trusts Jennifer N. Brudno overall

1. J. Kochenderfer
2. Kathryn M. Cappell
3. S. Rafiq

Papers from Jennifer N. Brudno's perspective

Ordered by how strongly the researchers Jennifer N. Brudno trusts endorse each paper. Same corpus, a different order for every researcher.

1. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia (Science Translational Medicine)
2. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia (Science Translational Medicine)
3. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia (Science Translational Medicine)
4. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells (Cancer Discovery)
5. Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia (New England Journal of Medicine)
6. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells (Nature Medicine)
7. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia (New England Journal of Medicine)
8. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities (Nature Reviews Clinical Oncology)
9. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia (New England Journal of Medicine)
10. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. (Blood)

Their papers

• Toxicities of chimeric antigen receptor T cells: recognition and management. (2016) — 1,293 citations
• T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. (2016) — 722 citations
• Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management (2018) — 805 citations
• T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. (2018) — 652 citations
• ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells (2018) — 3,090 citations